Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1

Journal of Cellular Physiology

Volumn 210, Issue 2, 2007, Pages 352-357

  Bodine, Peter V N ^a   Seestaller Wehr, Laura ^a   Kharode, Yogendra P ^a   Bex, Frederick J ^a   Komm, Barry S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRIZZLED PROTEIN; PARATHYROID HORMONE[1-34]; PROTEIN INHIBITOR; PROTEIN SFRP 1; WNT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE DELETION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE DETERMINATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; REGULATORY MECHANISM; TRABECULAR BONE;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; OSTEOGENESIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TERIPARATIDE; WNT PROTEINS;

ANIMALIA;

EID: 33845665838     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20834     Document Type: Article

References (59)

1. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PVN, Robinson JA, Bhat B, Moran RA, Bex F. 2003. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18(6):960-974.
2. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577-4583.
3. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP. 2002. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17(9):1570-1578.
4. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. 2004. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18(5):1222-1237.
5. Bodine PVN, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, Scrimo MJ, Bhat RA, Stauffer B, Green J, Stein GS, Lian JB, Komm BS. 2005. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96:1212-1230.
6. Bodine PVN, Robinson JA, Bhat RA, Billiard J, Bex FJ, Komm BS. 2006. The role of Wnt signaling in bone and mineral metabolism. Clin Rev Bone Miner Metab 4:73-96.
7. Bollerslev J, Wilson SG, Dick M, Islam FM, Ueland T, Palmer L, Devine A, Prince RL. 2005. LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone 36(4):599-606.
8. Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F, Rizzoli R, Ferrari SL. 2005. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20(4):635-643.
9. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513-1521.
10. Brixen KT, Christensen PM, Ejersted C, Langdahl BL. 2004. Teriparatide (biosynthetic human parathyroid hormone 1-34): A new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 94:260-270.
11. Chan SD, Karpf DB, Fowlkes ME, Hooks M, Bradley MS, Vuong V, Bambino T, Liu MY, Arnaud CD, Strewler GJ, Nissenson RA. 1992. Two homologs of the Drosophila polarity gene frizzled (fz) are widely expressed in mammalian tissues. J Biol Chem 267(35):25202-25207.
12. Chen AE, Ginty DD, Fan C-M. 2005. Protein kinase A signaling via CREB control myogenesis induced by Wnt proteins. Nature 433:317-322.
13. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK. 2002. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143(10):4038-4047.
14. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE. 2004. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet 74(5):866-875.
15. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, Kim DH, Ioka RX, Ono M, Tomoyori H, Okubo M, Murase T, Kamataki A, Yamamoto J, Magoori K, Takahashi S, Miyamoto Y, Oishi H, Nose M, Okazaki M, Usui S, Imaizumi K, Yanagisawa M, Sakai J, Yamamoto TT. 2003. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 100(1):229-234.
16. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280(39):33132-33140.
17. Goltzman D. 2002. Discoveries, drugs and skeletal disorders. Nature Rev Drug Discov 1(10):784-796.
18. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marceline J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, The Osteoporosis-Pseudoglioma Syndrome Collaborative G. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4):513-523.
19. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. 1999. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104(4):439-446.
20. Johnson ML, Harnish K, Nusse R, Van Hul W. 2004. LRP5 and Wnt signaling: A union made for bone. J Bone Miner Res 19(11):1749-1757.
21. Jones SE, Jomary C. 2002. Secreted Frizzled-related proteins: Searching for relationships and patterns. Bioessays 24(9):811-820.
22. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157(2):303-314.
23. Kawano Y, Kypta R. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116(Pt 13):2627-2634.
24. Keller H, Kneissel M. 2005. SOST is a target gene for PTH in bone. Bone 37(2):148-158.
25. Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K. 2005. The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146(4):1983-1990.
26. Koay MA, Woon PY, Zhang Y, Miles LJ, Duncan EL, Ralston SH, Compston JE, Cooper C, Keen R, Langdahl BL, MacLelland A, O'Riordan J, Pols HA, Reid DM, Uitterlinden AG, Wass JA, Brown MA. 2004. Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res 19(10):1619-1627.
27. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK. 2005. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146(11):4584-4596.
28. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. 2000. The Wnt/Ca2+ pathway: A new vertebrate Wnt signaling pathway takes shape. Trends Genet 16(7):279-283.
29. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. 2005. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95(6):1178-1190.
30. Lau HHL, Ng MYM, Ho AYY, Luk KDK, Rung AWC. 2005. Genetic and environmental determinants of bone mineral density in Chinese women. Bone 36:700-709.
31. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70(1):11-19.
32. Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781-810.
33. Martin TJ. 2004. Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 15:49-50.
34. Martin TJ. 2005. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115(9):2322-2324.
35. Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC. 2005. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115(9):2402-2411.
36. Miller JR. 2002. The Wnts. Genome Biology 3(1):REVIEWS3001.3001-3001. 3015.
37. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. 2001. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142(10):4349-4356.
38. Mizuguchi T, Furuta I, Watanabe Y, Tsukamoto K, Tomita H, Tsujihata M, Ohta T, Kishino T, Matsumoto N, Minakami H, Niikawa N, Yoshiura K. 2004. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J Hum Genet 49(2):80-86.
39. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. 2004. WNT and beta-catenin signalling: Diseases and therapies. Nature Rev Genet 5(9):691-701.
40. Morley P, Whitfield JF, Willick GE. 2001. Parathyroid hormone: An anabolic treatment for osteoporosis. Curr Pharm Des 7:671-687.
41. Patel MS, Karsenty G. 2002. Regulation of bone formation and vision by LRP5. N Engl J Med 346(20):1572-1574.
42. Pourquie O. 2005. A new canon. Nature 433:208-209.
43. Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. 2003. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 278(22):19723-19731.
44. Quattrocchi E, Kourlas H. 2004. Teriparatide: A review. Clin Ther 26(6):841-854.
45. Sawakami K, Rohling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH. 2006. The WNT co-receptor LRP5 is essential for skeletal mechanotransduction, but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281(33):23698-23711.
46. Sharpe C, Lawrence N, Martinez Arias A. 2001. Wnt signalling: A theme with nuclear variations. Bioessays 23(4):311-318.
47. Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K. 2006. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147(5):2583-2590.
48. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. 2003. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. [see comment]. J Cell Biol 162(5):899-908.
49. Turgeman G, Zilberman Y, Zhou S, Kelly P, Moutsatsos IK, Kharode YP, Borella LE, Bex FJ, Komm BS, Bodine PVN, Gazit D. 2002. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem 86(3):461-474.
50. Urano T, Shiraki M, Ezura Y, Fujita M, Sekine E, Hoshino S, Hosoi T, Orimo H, Emi M, Ouchi Y, Inoue S. 2004. Association of a single-nucleotide polymorphism in low-density lipoprotein receptor-related protein 5 gene with bone mineral density. J Bone Miner Metabolism 22(4):341-345.
51. van Bezooijen RL, ten Dijke P, Papappulos SE, Lowick CWGM. 2005. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327.
52. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W. 2003. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72(3):763-771.
53. Veeman MT, Axelrod JD, Moon RT. 2003. A second canon: functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5(3):367-377.
54. Wang L, Quarles LD, Spurney RF. 2004. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). J Bone Miner Res 19(10):1661-1670.
55. Westendorf JJ, Kahler RA, Schroeder TM. 2004. Wnt signaling in osteoblasts and bone diseases. Gene 341:19-39.
56. Weston CH, Davis RJ. 2002. The JNK signal transduction pathway. Curr Opin Genet Dev 12:14-21.
57. Wodarz A, Nusse R. 1998. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14:59-88.
58. Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, Lindsay R. 2003. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32(5):513-520.
59. Zorn AM. 2001. Wnt signaling: antagonistic dickkopfs. Curr Biol 11:R592-R595.